Charles River Laboratories International, Inc.

As of October 3, 2025, Charles River Laboratories shows a mildly bullish trend with positive momentum from weekly and monthly MACD indicators, despite some caution from the KST and mixed signals from Bollinger Bands, while the stock has outperformed the S&P 500 recently but underperformed over the past five years.

As of October 3, 2025, Charles River Laboratories shows a mildly bullish technical trend, with positive momentum indicated by weekly MACD and daily moving averages, despite underperforming the S&P 500 with year-to-date and one-year returns of -3.94% and -6.47%, respectively.

As of October 3, 2025, Charles River Laboratories shows a mildly bullish technical trend, supported by bullish daily moving averages and weekly MACD, despite underperforming the S&P 500 with a year-to-date return of -3.94%.

As of September 8, 2025, Charles River Laboratories has a mildly bullish technical trend, with mixed indicators and underperformance compared to the S&P 500, showing a year-to-date return of -14.96% versus the S&P's 12.22%.

As of May 7, 2025, Charles River Laboratories is considered risky and overvalued with a P/E ratio of 22, significantly higher than peers, and has underperformed the S&P 500 with a year-to-date return of -14.96% and a 10-year return of -28.51%.

As of May 7, 2025, Charles River Laboratories is considered overvalued and risky, with a P/E ratio of 22, modest profitability metrics, and significant underperformance compared to the S&P 500.

As of May 23, 2025, Charles River Laboratories is in a mildly bearish trend, indicated by daily moving averages and bearish signals from monthly MACD and KST, despite some short-term strength suggested by weekly indicators.

As of March 2022, the management team of Charles River Laboratories includes Chairman and CEO James Foster, Lead Independent Director Dr. George Milne, and Independent Directors Dr. Nancy Andrews, Mr. Robert Bertolini, Mr. Stephen Chubb, and Director Mr. George Llado. They are responsible for guiding the company's strategic direction and operations.

Charles River Laboratories International, Inc. is a contract research organization specializing in laboratory animal medicine and science, with net sales of $984 million and a market cap of approximately $7.15 billion as of March 2025. Key financial metrics include a P/E ratio of 22.00 and a return on equity of 9.99%.

As of Jun 18, Charles River Laboratories International, Inc. has a market capitalization of 7,145.56 million, with net sales of 4,022.60 million and a net profit of -23.31 million over the latest four quarters. Shareholder's funds are 3,461.50 million, and total assets are 7,528.35 million.